Natural History of <i>Sudan ebolavirus</i> to Support Medical Countermeasure Development
Caroline Carbonnelle,
Marie Moroso,
Delphine Pannetier,
Sabine Godard,
Stéphane Mély,
Damien Thomas,
Aurélie Duthey,
Ophélie Jourjon,
Orianne Lacroix,
Béatrice Labrosse,
Hervé Raoul,
Karen L. Osman,
Francisco J. Salguero,
Yper Hall,
Carol L. Sabourin,
Michael J. Merchlinsky,
James P. Long,
Lindsay A. Parish,
Daniel N. Wolfe
Affiliations
Caroline Carbonnelle
Inserm, Laboratoire P4 Jean Mérieux, 69007 Lyon, France
Marie Moroso
Inserm, Laboratoire P4 Jean Mérieux, 69007 Lyon, France
Delphine Pannetier
Inserm, Laboratoire P4 Jean Mérieux, 69007 Lyon, France
Sabine Godard
Inserm, Laboratoire P4 Jean Mérieux, 69007 Lyon, France
Stéphane Mély
Inserm, Laboratoire P4 Jean Mérieux, 69007 Lyon, France
Damien Thomas
Inserm, Laboratoire P4 Jean Mérieux, 69007 Lyon, France
Aurélie Duthey
Inserm, Laboratoire P4 Jean Mérieux, 69007 Lyon, France
Ophélie Jourjon
Inserm, Laboratoire P4 Jean Mérieux, 69007 Lyon, France
Orianne Lacroix
Inserm, Laboratoire P4 Jean Mérieux, 69007 Lyon, France
Béatrice Labrosse
Inserm, Laboratoire P4 Jean Mérieux, 69007 Lyon, France
Hervé Raoul
Inserm, Laboratoire P4 Jean Mérieux, 69007 Lyon, France
Karen L. Osman
UK Health Security Agency, Porton Down, Salisbury, Wiltshire SP4 0JG, UK
Francisco J. Salguero
UK Health Security Agency, Porton Down, Salisbury, Wiltshire SP4 0JG, UK
Yper Hall
UK Health Security Agency, Porton Down, Salisbury, Wiltshire SP4 0JG, UK
Carol L. Sabourin
U.S. Department of Health and Human Services (DHHS), Tunnell Government Services, Inc., Supporting Biomedical Advanced Research & Development Authority (BARDA), Assistant Secretary for Preparedness and Response (ASPR), Washington, DC 20201, USA
Michael J. Merchlinsky
U.S. Department of Health and Human Services (DHHS), CBRN Vaccines, Biomedical Advanced Research & Development Authority (BARDA), Assistant Secretary for Preparedness and Response (ASPR), Washington, DC 20201, USA
James P. Long
U.S. Department of Health and Human Services (DHHS), Tunnell Government Services, Inc., Supporting Biomedical Advanced Research & Development Authority (BARDA), Assistant Secretary for Preparedness and Response (ASPR), Washington, DC 20201, USA
Lindsay A. Parish
U.S. Department of Health and Human Services (DHHS), CBRN Vaccines, Biomedical Advanced Research & Development Authority (BARDA), Assistant Secretary for Preparedness and Response (ASPR), Washington, DC 20201, USA
Daniel N. Wolfe
U.S. Department of Health and Human Services (DHHS), CBRN Vaccines, Biomedical Advanced Research & Development Authority (BARDA), Assistant Secretary for Preparedness and Response (ASPR), Washington, DC 20201, USA
Sudan ebolavirus (SUDV) is one of four members of the Ebolavirus genus known to cause Ebola Virus Disease (EVD) in humans, which is characterized by hemorrhagic fever and a high case fatality rate. While licensed therapeutics and vaccines are available in limited number to treat infections of Zaire ebolavirus, there are currently no effective licensed vaccines or therapeutics for SUDV. A well-characterized animal model of this disease is needed for the further development and testing of vaccines and therapeutics. In this study, twelve cynomolgus macaques (Macaca fascicularis) were challenged intramuscularly with 1000 PFUs of SUDV and were followed under continuous telemetric surveillance. Clinical observations, body weights, temperature, viremia, hematology, clinical chemistry, and coagulation were analyzed at timepoints throughout the study. Death from SUDV disease occurred between five and ten days after challenge at the point that each animal met the criteria for euthanasia. All animals were observed to exhibit clinical signs and lesions similar to those observed in human cases which included: viremia, fever, dehydration, reduced physical activity, macular skin rash, systemic inflammation, coagulopathy, lymphoid depletion, renal tubular necrosis, hepatocellular degeneration and necrosis. The results from this study will facilitate the future preclinical development and evaluation of vaccines and therapeutics for SUDV.